Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)
Open Access
- 18 December 2021
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 126 (7) , 1047-1054
Abstract
Background: Predictive models based on radiomics features are novel, highly promising approaches for gynaecological oncology. Here, we wish to assess the prognostic value of the newly discovered Radiomic Prognostic Vector (RPV) in an independent cohort of high-grade serous ovarian cancer (HGSOC) patients, treated within a Centre of Excellence, thus avoiding any bias in treatment quality. Methods: RPV was calculated using standardised algorithms following segmentation of routine preoperative imaging of patients (n = 323) who underwent upfront debulking surgery (01/2011-07/2018). RPV was correlated with operability, survival and adjusted for well-established prognostic factors (age, postoperative residual disease, stage), and compared to previous validation models. Results: The distribution of low, medium and high RPV scores was 54.2% (n = 175), 33.4% (n = 108) and 12.4% (n = 40) across the cohort, respectively. High RPV scores independently associated with significantly worse progression-free survival (PFS) (HR = 1.69; 95% CI:1.06–2.71; P = 0.038), even after adjusting for stage, age, performance status and residual disease. Moreover, lower RPV was significantly associated with total macroscopic tumour clearance (OR = 2.02; 95% CI:1.56–2.62; P = 0.00647). Conclusions: RPV was validated to independently identify those HGSOC patients who will not be operated tumour-free in an optimal setting, and those who will relapse early despite complete tumour clearance upfront. Further prospective, multicentre trials with a translational aspect are warranted for the incorporation of this radiomics approach into clinical routine.Keywords
This publication has 29 references indexed in Scilit:
- Principles and methods of integrative genomic analyses in cancerNature Reviews Cancer, 2014
- Staging classification for cancer of the ovary, fallopian tube, and peritoneumInternational Journal of Gynecology & Obstetrics, 2013
- Stromal Responses among Common Carcinomas Correlated with Clinicopathologic FeaturesClinical Cancer Research, 2013
- Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancerCritical Reviews in Oncology/Hematology, 2013
- Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?Journal of Nuclear Medicine, 2012
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancerGynecologic Oncology, 2011
- Prognostic Impact of Additional Extended Surgical Procedures in Advanced-Stage Primary Ovarian CancerAnnals of Surgical Oncology, 2009
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009